AUA 2023热点速递：肾癌的临床进展

纪长威; 郭宏骞

doi:10.13201/j.issn.1001-1420.2023.06.010

AUA 2023热点速递：肾癌的临床进展

纪长威^1,2,
郭宏骞^1,2, ,

- 1.
  南京大学医学院附属鼓楼医院泌尿外科(南京，210008)
- 2.
  南京大学泌尿外科学研究所

详细信息

通讯作者: 郭宏骞，E-mail：dr.ghq@nju.edu.cn

中图分类号: R737.11

收稿日期: 2023-05-10

刊出日期: 2023-06-06

Highlights from AUA 2023: clinical progress of kidney cancer

JI Changwei^1,2,
GUO Hongqian^1,2, ,

- 1.
  Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Nanjing, 210008, China
- 2.
  Institute of Urology, Nanjing University

More Information

Corresponding author: GUO Hongqian, E-mail: dr.ghq@nju.edu.cn

Received Date: 10 May 2023

Publish Date: 06 June 2023

摘要

摘要: 第118届美国泌尿外科协会(AUA)年会于2023年4月28日—5月1日在美国芝加哥举行。会议就肾癌方面多个临床热点与争议话题进行了报道与讨论，本文就肾癌诊断工具、主动监测、能量消融、围手术期肾功能评估、肾动脉阻断方式等部分内容做简要介绍。
- 肾癌 /
- 主动监测 /
- 能量消融 /
- 肾部分切除术
Abstract: The 118th Annual Meeting of the American Urological Association(AUA) was held in Chicago, USA from April 28 to May 1, 2023. The meeting reported and discussed many clinical hotspots and controversial topics in kidney cancer. This article briefly introduces the latest progress in kidney cancer diagnostic tools, active surveillance, energy ablation, perioperative renal function evaluation, and renal artery occlusion methods.
- kidney cancer /
- active surveillance /
- energy ablation /
- partial nephrectomy

HTML全文

参考文献(8)

[1]	Shuch B, Pantuck AJ, Bernhard JC, et al. LBA03-01 89Zr-DFO-GIRENTUXIMAB for PET/CT imaging of indeterminate renal masses-results from phase 3 ZIRCON study[J]. J Urol, 2023, 209(Supplement 4): e1192.
[2]	Pessoa RR, Nabavizadeh R, Arafa A, et al. PD17-09 CD70-POSITIVE extracellular vesicles for detection of clear-cell renal cell carcinoma[J]. J Urol, 2023, 209(Supplement 4): e499.
[3]	Alkhatib KY, Cheaib J, Singla N, et al. PD08-11 active surveillance versus primary intervention for clinical T_1akidney tumors: twelve-year experience of the dissrm prospective comparative study[J]. J Urol, 2023, 209(Supplement 4): e237.
[4]	Altok M, Menon A, Aly A, et al. PD08-12 predictors of progression and delayed intervention in small renal mass patients undergoing active surveillance without health-related selection bias[J]. J Urol, 2023, 209(Supplement 4): e237.
[5]	Rathi N, Lewis K, Attawettayanon W, et al. PD43-01 linear measurements at point of care to estimate split renal function and predict functional outcomes after radical nephrectomy[J]. J Urol, 2023, 209(Supplement 4): e1117. doi: 10.1038/s41598-023-33236-6
[6]	Attawettayanon W, Yasuda Y, Zhang J, et al. PD43-03 functional recovery after partial nephrectomy in a solitary kidney[J]. J Urol, 2023, 209(Supplement 4): e1118.
[7]	Mastroianni R, Tuderti G, Anceschi U, et al. MP47-05 sutureless off-clamp robot-assisted partial nephrectomy: indication, feasibility and functional outcomes[J]. J Urol, 2023, 209(Supplement 4): e644. doi: 10.1007/s13730-022-00770-7
[8]	Flammia RS, Anceschi U, Brassetti A, et al. PD07-03 unveil the interplay between baseline renal function, warm ischemia time and tumor complexity when assessing renal functional outcomes of on-vs off-clamp robot-assisted partial nephrectomy[J]. J Urol, 2023, 209(Supplement 4): e162. doi: 10.1007/s00381-023-05897-1